A case of Raynaud's phenomenon in mixed connective tissue disease responding to Rituximab therapy - Response [14]

Rheumatology

Volumn 46, Issue 10, 2007, Pages 1628-1629

  Dunkley, L ^a   Green, Mike ^a   Gough, A ^a  

^a Harrogate Health Care Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BOSENTAN; BUDESONIDE PLUS FORMOTEROL; CYCLOSPORIN; ETANERCEPT; FLUOXETINE; IMMUNOGLOBULIN; LOSARTAN; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; METHYLPREDNISOLONE; MONTELUKAST; MORPHINE SULFATE; NIFEDIPINE; NIFEDIPINE SR; OPIATE; PREDNISOLONE; RAMIPRIL; RITUXIMAB; SALBUTAMOL; SILDENAFIL; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANAMNESIS; ASTHMA; BRONCHIOLITIS; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LETTER; LUNG BIOPSY; LUNG FUNCTION TEST; MIXED CONNECTIVE TISSUE DISEASE; PAIN; PLASMAPHERESIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SMOKING CESSATION; TREATMENT DURATION; NOTE; TREATMENT FAILURE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; MIXED CONNECTIVE TISSUE DISEASE; RAYNAUD DISEASE; TREATMENT FAILURE;

EID: 34848842811     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem208     Document Type: Letter

References (10)

1. Haroon M, O'Gradaigh D, Foley-Nolan D. A case of Raynaud's phenomenon in mixed connective tissue disease responding to Rituximab therapy. Rheumatology 2007;46:718-9.
2. Wells AU, Nicholson AG, Hansell DM, du Bois RM. Respiratory bronchiolitis-associated interstitial lung disease. Semin Respir Crit Care Med 2003;24:585-94.
3. Silverman G, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthrit Rheum 2003;48:1484-92.
4. Gliddon AE, Dore CJ, Maddison PJ. Quins Trial study group. Prevention of vascular damage in scleroderma: Results of a randomised, double blind, placebo-controlled trial of the ace inhibitor Quinapril in limited cutaneous systemic sclerosis. Rheumatology 2007;46(Suppl 1):i9.
5. Denton CP, Howell K, Stratton RJ, Black CM. Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: A pilot study. Clin Exp Rheum 2000;18:499-502.
6. Korn JH, Mayes M, Matucci Cerinic M et al. Digital ulcers in systemic sclerosis (RAPIDS-1 study group). Arthrit Rheum 2004;50:3985-93.
7. Rech J, Kallert S, Hueber AJ, Requadt C, Kalden JR, Schulze-Koops H. Combination of immunoadsorption and CD20 antibody therapy in a patient with mixed connective tissue disease. Rheumatology 2006;45:490-1.
8. Edwards JCW, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheum 2006;20:915-28.
9. Denton CP, Black CM. Targeted therapy comes of age in scleroderma. Trends Immunol 2005;26:596-602.
10. Leandro MJ, Cambridge G, Edwards JCW, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients. Rheumatology 2005;44:1542-5.